Ideaya rises as it starts early-stage trial of combination of cancer drugs

Shares of drugmaker Ideaya Biosciences IDYA.O rise 2% to $30.80 premarket

Co says it began treating patients in an early-stage trial of a combination of two experimental cancer drugs

The study tests IDE849, which targets DLL3, a protein found on some cancer cells, with IDE161, which blocks a DNA repair process tumors use to survive

Co says the combo aims to cause more DNA damage in cancer cells, making tumors harder to grow back

Trial includes patients with solid tumors such as small cell lung cancer and melanoma, across North America, Europe, Australia, South America and Asia

In an ongoing study of IDE849 alone, co says 3 of 4 previously treated small cell lung cancer patients showed partial tumor shrinkage

Co says more data on the combo and IDE849 alone are expected in the second half of 2026

Shares up ~35% in 2025